Author: healthylife7

Cemacabtagene ansegedleucel (cema-cel, formerly ALLO-501A) is being evaluated in the Phase II ALPHA3 trial in patients who respond to first-line chemoimmunotherapy but remain positive for minimal residual disease. At day 45, plasma circulating tumour DNA had decreased by a median of 97.7 per cent with cema-cel, versus a 26.6 per cent increase under observation. No…

Read More

For a full list of recruits and where they are committed for each of the active classes, check out ourcomplete database. To learn more about the gymnasts, click their name to visit their CGN profile, where you’ll find high scores, links to their score page(s), their social media accounts, and more

Read More